Overactive bladders later this year could become the next big frontier for Botox, the anti-wrinkle drug, and significantly boost sales of the $1.5 billion-a-year product, according to company Chief Executive David Pyott.
Allergan earlier on Wednesday reported profit growth for the second-quarter, fueled largely by sales of Botox to smooth wrinkles and for a growing range of medical uses.
Overactive bladder, caused by uncontrollable contractions of the bladder, causes frequent urination, urgent need to urinate and inability to control urination.
"Current drugs for overactive bladder just don't work that well," Pyott said in an interview, "and studies show that after a year 70 percent of patients don't respond to treatment."
Standard treatments, pills called anticholinergics, including oxybutynin and GlaxoSmithKline PLC's Vesicare, are associated with dry mouth and can cause constipation and other side effects.
A single injection of Botox into the bladder can provide significant relief for up to a year and significantly improve quality of life, Pyott said, particularly for adults who now need to wear diapers.
Pyott said he expects U.S. regulators this year to approve Botox for those whose overactive bladder is caused by multiple sclerosis and spinal cord injury, which together number about 350,000 patients in the United States.
Several years later, Allergan hopes to win approval to market it more widely to tens of millions of people with nocturia -- meaning those who need to get up repeatedly during the night to urinate.
Pyott declined to forecast sales of Botox for overactive bladder but said Wall Street analysts are projecting annual sales of up to $500 million. "For a company with a revenue base of $5.2 billion to $5.4 billion, another $500 million franchise is kind of cool," he said.
Botox, whose active ingredient is a toxin that blocks nerve signals, gets about half its sales from reducing wrinkles and the rest from a number of medical uses, including treatment of migraine headaches and spasticity.
The product's second-quarter sales rose 16 percent to $418 million, helped by its recent approval to treat migraines and a somewhat stronger economy, which enabled more patients to pay out of pocket for cosmetic uses.
Allergan said on Wednesday that net income rose to $249 million, or 79 cents per share, from $241 million, or 78 cents per share, in the year-earlier quarter.
Excluding special items, the company earned 96 cents per share. Analysts on average expected 95 cents, according to Thomson Reuters I/B/E/S.
Sales rose almost 14 percent to $1.40 billion, topping Wall Street forecasts of $1.34 billion. They would have increased 9.6 percent if not for the weaker dollar, which drives up the value of sales in overseas markets.
"Strong top-line trends continue," JP Morgan analyst Chris Schott said in a research note, "and we expect these dynamics to continue throughout 2011."
Schott said Allergan boosted its 2011 overall sales forecast by $120 million to $170 million. But he noted the company reported higher-than-expected spending in the second quarter on sales, general and administrative expenses.
Sales of prescription eye medicines, by far the company's biggest business, rose 14 percent to $658 million.
Sales of medical devices rose 12 percent to $245 million, fueled by demand for breast implants and dermal fillers.
But sales of the company's Lap Band product, to treat obesity, continued to decline, as did sales of the company's Latisse eyelash-growth product.
Allergan nudged up its full-year profit forecast to between $3.59 and $3.63 per share, excluding special items. It had previously expected $3.56 to $3.62.
Copyright 2011 Thomson Reuters. Click for Restrictions.
Our 2024 Coverage Needs You
It's Another Trump-Biden Showdown — And We Need Your Help
The Future Of Democracy Is At Stake
Our 2024 Coverage Needs You
Your Loyalty Means The World To Us
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
The 2024 election is heating up, and women's rights, health care, voting rights, and the very future of democracy are all at stake. Donald Trump will face Joe Biden in the most consequential vote of our time. And HuffPost will be there, covering every twist and turn. America's future hangs in the balance. Would you consider contributing to support our journalism and keep it free for all during this critical season?
HuffPost believes news should be accessible to everyone, regardless of their ability to pay for it. We rely on readers like you to help fund our work. Any contribution you can make — even as little as $2 — goes directly toward supporting the impactful journalism that we will continue to produce this year. Thank you for being part of our story.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
It's official: Donald Trump will face Joe Biden this fall in the presidential election. As we face the most consequential presidential election of our time, HuffPost is committed to bringing you up-to-date, accurate news about the 2024 race. While other outlets have retreated behind paywalls, you can trust our news will stay free.
But we can't do it without your help. Reader funding is one of the key ways we support our newsroom. Would you consider making a donation to help fund our news during this critical time? Your contributions are vital to supporting a free press.
Contribute as little as $2 to keep our journalism free and accessible to all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
As Americans head to the polls in 2024, the very future of our country is at stake. At HuffPost, we believe that a free press is critical to creating well-informed voters. That's why our journalism is free for everyone, even though other newsrooms retreat behind expensive paywalls.
Our journalists will continue to cover the twists and turns during this historic presidential election. With your help, we'll bring you hard-hitting investigations, well-researched analysis and timely takes you can't find elsewhere. Reporting in this current political climate is a responsibility we do not take lightly, and we thank you for your support.
Contribute as little as $2 to keep our news free for all.
Can't afford to donate? Support HuffPost by creating a free account and log in while you read.
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. Would you consider becoming a regular HuffPost contributor?
Dear HuffPost Reader
Thank you for your past contribution to HuffPost. We are sincerely grateful for readers like you who help us ensure that we can keep our journalism free for everyone.
The stakes are high this year, and our 2024 coverage could use continued support. If circumstances have changed since you last contributed, we hope you'll consider contributing to HuffPost once more.
Support HuffPostAlready contributed? Log in to hide these messages.